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Tumor expression of human chorionic gonadotropin beta mRNA and prognosis 
of prostate cancer treated by radical prostatectomy 
Abstract 
The beta subunit of human chorionic gonadotropin (hCGβ) is encoded by six genes (CGB) 
classified as type I and type II.  CGB mRNA is produced in large amounts by trophoblastic tissues 
and in small amounts by several cancerous tissues including prostate cancer and by a few benign 
tissues, including the prostate. Quantitative reverse-transcription polymerase chain reaction (RT-
qPCR) was used to study the expression levels of all CGB mRNAs together (total CGB mRNA) and 
the two types of CGB mRNA separately in non-cancerous (n = 74) and cancerous prostatic tissue 
obtained by radical prostatectomy (n = 193). RNA was isolated from formalin-fixed paraffin-
embedded (FFPE) samples and mRNA levels of CGB were correlated with disease-specific 
survival. Total CGB mRNA concentrations were significantly lower (p < 0.0001) in cancerous than 
non-cancerous prostatic tissue. Separate analysis of type I CGB and type II CGB  mRNA showed 
that both type I CGB (p < 0.0001) and type II CGB mRNA  (p = 0.007) are lower in cancerous 
tissue than in non-cancerous tissue. Low type II CGB mRNA level in cancerous tissue of was 
associated with shorter cancer-specific survival (p = 0.001) of prostate cancer patients treated by 
radical prostatectomy. 
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Introduction 
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Prostate cancer is the most common non-skin cancer in males. Its incidence has increased 
dramatically since the introduction of opportunistic screening based on determination of prostate-
specific antigen (PSA) and biopsy of patients with elevated serum concentrations of PSA. While 
this has reduced mortality, it has also led to overdiagnosis and overtreatment [1]. These can be 
reduced by active surveillance of patients with favorable Gleason score, which is the most reliable 
prognostic factor. However, additional prognostic factors are needed. 
Human chorionic gonadotropin (hCG) is a heterodimeric hormone consisting of an α 
(hCGα) and a β subunit (hCGβ). hCG is produced in large amounts by the placenta during 
pregnancy and also by trophoblastic tumors and many gonadal germ cell tumors. Isolated 
production of hCGβ is also observed in 30 – 50% of most non-trophoblastic tumors, and elevated 
serum concentration of hCGβ is associated with several cancers [2-3]. hCGβ is encoded by six CGB 
genes: CGB1, CGB2, CGB (originally called CGB3), CGB5, CGB7, and CGB8 [4]. CGB, CGB5, 
and CGB8 produce one protein-coding mRNA transcript each, while CGB7 has three protein coding 
transcripts and two non-coding transcripts, the so-called processed transcripts. CGB1 and CGB2, 
earlier considered pseudogenes, have two transcripts each, with two different translation initiation 
sites (AUG1 and AUG2). It has been speculated that the AUG2 site is a common start site for all 
hCGβ proteins, while the AUG1 site in CGB1 and CGB2 using a different open reading frame 
would encode a non-hCGβ protein, the structure and function of which are unknown [5].  
Expression of the various CGB genes at the mRNA level has been found in several 
non-trophoblastic tumors, including those of the breast, thyroid, kidney, bladder, and prostate [6-
10]. CGB7 and, according to recent information, CGB2, encode an alanine (GCC) at position 117, 
whereas CGB, CGB5, CGB8, and CGB1 encode aspartic acid (GAC) at this position. Based on the 
difference at amino acid 117, CGB, CGB5, and CGB8 have been called type II genes, while CGB7 
is classified as a type I gene. The type I gene has been reported to be expressed in many non-
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transformed tissues and type II genes in placental and malignant tissues [6].  However, other studies 
show that expression of the various genes is not specific for cancerous or non-cancerous tissues [5, 
11]. Furthermore, increased expression of CGB1 and CGB2, which were earlier considered 
pseudogenes, has been found in ectopic and molar pregnancies and in the male reproductive tract 
[12].  
To further evaluate the role of hCGβ in prostate cancer, we studied the expression 
levels of CGB mRNAs in non-cancerous and cancerous prostate tissue and compared these using 
disease-specific and overall survival as endpoints. 
Materials and Methods 
Cell lines 
As standards for quantitative RT-PCR (RT-qPCR) of CGB, we used mRNA isolated from T24 
bladder cancer (type I genes) and JEG-3 trophoblast cell lines (type II genes) (American Type 
Culture Collection, Rockville, MD, USA). The cells were grown at 37°C in a humidified 
atmosphere with 5% CO2. Cells were maintained in RPMI 1640 medium supplemented with 10% 
heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 000 units/l penicillin, and 100 µg/l 
streptomycin.  
Patients and Samples 
Clinical characteristics of the prostate cancer patients are shown in Table 1. FFPE (formalin-fixed 
paraffin-embedded) samples were collected from 193 prostate cancer patients undergoing radical 
prostatectomy during 1984-1998. Median follow-up time was 16.1 years (range 0.57 – 26.10 years). 
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RNA was extracted from FFPE samples of all 193 patients and adjacent non-cancerous tissue were 
extracted from 74 patients out of 193. Total sample number and number of analyzed samples with 
different methods as well as number of samples with detectable amounts of different mRNAs are 
shown in Table 2. 
RNA isolation from FFPE samples and cell lines 
For isolation of total RNA from FFPE tissue, representative parts of the tumor and non-cancerous 
tissue were selected by a pathologist according with relevant diagnostic standards in the field 
[13-14] and two 1 mm cylinders were cut with a puncher from both cancerous and non-cancerous 
sites. Cancerous lesions were specimens containing the highest Gleason score and dominant tumor. 
The tissue was homogenized manually and paraffin was removed by incubating twice in 98% 
octane for 15 min at 55 °C and then washed twice with absolute ethanol. The tissue was air-dried 
and treated with 50 µl Proteinase K (20 mg/ml, Finnzymes, Espoo, Finland) for 3 h at 37 °C. Three 
hundred microliters of 4 M guanidium isothiocyanate buffer and 1 µg of yeast tRNA were added. 
The samples were incubated at 95 °C for 30 min, followed by centrifugation through a Qiashredder 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions.  
Total RNA was extracted by use of a modification of the protocol of Chomczynski 
and Sacchi [15] as follows. One volume of water-saturated phenol and 0.1 volume of 2 M sodium 
acetate were added to the sample, which was mixed thoroughly by repeated inversion, and 
incubated on ice for 30 min. The sample was transferred to a prespun 2 ml Phase Lock Gel Heavy 
Tube (Eppendorf), and 90 µl of chloroform - isoamyl alcohol (49:1) was added and mixed by 
repeated gentle inversion. After centrifugation at 5200 g for 5 min to separate the phases, 300 µl of 
phenol–chloroform–isoamyl alcohol (50:49:1) was added to the aqueous phase and mixed 
thoroughly. After centrifuging at 5200 g for 5 min, the resulting aqueous phase was collected and 
SUPPLEMENTAL TABLE S1. MIQE checklist.
ITEM TO CHECK IMPORTANCE CHECKLIST
EXPERIMENTAL DESIGN
Definition of experimental and control  groups E Experimental Group (A): FFPE samples from patients with Prostate cancer,
Control groups (B): B1) non-ca tissue from same FFPE samples, B2)FFPE
samples from BPH patients
Number within each group E A: n= 193, B1= 74, B2= 47
Assay carried out by core lab or investigator's lab? D
Acknowledgement of authors' contributions D
SAMPLE
Description E FFPE Prostate tissue from Radical Prostatectomy
     Volume/mass of sample processed D
    Microdissection or macrodissection E macrodissection
Processing procedure E
     If frozen - how and how quickly? E not frozen
     If fixed - with what, how quickly? E fixed with 4% formalin (pH 7.4) overnight after 0-2h from prostatectomy
Sample storage conditions and duration (especially for FFPE samples) E room temperature appr. 1-26 years
NUCLEIC ACID EXTRACTION
Procedure and/or instrumentation E Total RNA was extracted by the protocol of Chomczynski and Sacchi with minor
modifivcations (described in text)
     Name of kit and details of any modifications E No kit was used
     Source of additional reagents used D
Details of DNase or RNAse treatment E The extracted total RNA was then DNase-treated by adding to 10 mg of RNA, 5 m l of 10x
DNase buffer (100 mM Tris, pH 7.5, 25 mM MgCl2, 5 mM CaCl2) and 10 units of
DNase I  and incubating for 30 min at 37°C, after which the DNase was inactivated for 5
min at 70°C. RNA was then precipitated with 5 m l of 2 M sodium acetate (pH 4.0) and
140 m l of 100% ethanol overnight at -20°C, after which the sample was centrifuged at
5200 g for 30 min at 4°C. The supernatant was carefully removed and the RNA pellet
washed with 200 m l of 70% ethanol, after which the sample was centrifuged at 5200 g
for 20 min at 4°C. The supernatant was removed, and the RNA was dissolved in 20 m l
of RNase-free water.
Contamination assessment (DNA or RNA) E reverse transcription controls (W/O enzyme) were performed in order to assess
the absence of DNA in the RNA sample.
Nucleic acid quantification E RNA concentration was determined by measuring te absorbance at 260 nm UV
light
     Instrument and method E NanoDrop 1000 (Thermo Scientific)
     Purity (A260/A280) D 1.9-2.0
     Yield D 500-1000 ng/µl
RNA integrity method/instrument E RNA integrity was not determined (RNA from FFPE samples is degraded)
    RIN/RQI or Cq of 3' and 5' transcripts E Not applicable
    Electrophoresis traces D
 Inhibition testing (Cq dilutions, spike or other) E We think that standard curve is sufficient to rule out the presence of inhibitors
in RT or PCR
REVERSE TRANSCRIPTION
Complete reaction conditions E Total RNA (450 ng) was denaturated for 5 min at 70°C and multiplex reverse-transcribed
in 5 µl reaction volume with RevertAid Premium  reverse transcriptase (Thermo Fisher
Scientific, Waltham, MA, USA) at 55°C for 30 min using gene-specific antisense primers
(Table 2a). After reverse transcription, the unbound reverse transcription primers were
degraded by Exonuclease I (New England Biolabs, Ipswitch, MA, USA) at 42°C for 45
min.
     Amount of RNA and reaction volume E Amount of RNA:450 ng, reaction volume 5 µl
    Priming oligonucleotide (if using GSP) and concentration E Gene specific primers for CGB type 1 and type 2 as well as Total CGB and
GAPDH. All in concentration 100 µM
     Reverse transcriptase and concentration E RevertAid Premium  reverse transcriptase (Thermo Fisher Scientific, Waltham,
MA, USA), concentration 200U/µl
     Temperature and time E  Temperature:55°C,Time:30 min
     Manufacturer of reagents and catalogue numbers D
Cqs with and without RT D*
Storage conditions of cDNA D
qPCR TARGET INFORMATION
If multiplex, efficiency and LOD of each assay. E
Sequence accession number E ENSG00000111640 (GAPDH); ENSG00000267631 (CGB1); ENSG00000104818
(CGB2); ENSG00000104827 (CGB); ENSG00000189052 (CGB5); ENSG00000196337
(CGb7); ENSG00000213030 (CGB8)
Location of amplicon D
     Amplicon length E (SYBR Green chemistry-PCR): GAPDH  127bp, CGB total 130 bp; TaqMan
chemistry: GAPDH 97 bp, type 1 and type 2 CGB 98 bp
  In silico specificity screen (BLAST, etc) E BLAST
     Pseudogenes, retropseudogenes or other homologs? D
          Sequence alignment D
     Secondary structure analysis of amplicon D
Location of each primer by exon or intron (if applicable) E
     What splice variants are targeted? E All known spice variants
qPCR OLIGONUCLEOTIDES
Primer sequences E Table 2a and 2b in paper
RTPrimerDB Identification Number D
Probe sequences D**
Location and identity of any modifications E No modifications were done
Manufacturer of oligonucleotides D
Purification method D
qPCR PROTOCOL
Complete reaction conditions E Real-time qPCR for GCB type I and type II as well as for GAPDH separately were carried
out with SensiFAST Probe Lo-ROX Kit (Bioline) with 4 pmol of each primer and 2 pmol
of hydrolysis probes in a final volume of 10 m l using Applied Biosystem 7500 Fast
Real-Time PCR System (Life Tecnologies, Carlstad, CA) and thermocycling conditions 95
˚C for 5 min, 40 cycles at 95 ˚C for 10s, at 65 ˚C for 20s. Endpoint RT-qPCR for total
CGB  and GAPDH separately was carried out with Dynamo HS SYBR Green 2 x master Mix
(Thermo Fisher Scientific) with 5 pmol of each primer in a final volume of 10.9 m l
using Applied Biosystem 7500 Fast Real-Time PCR System (Life Tecnologies, Carlstad,
CA) and thermocycling conditions 95 ˚C for 15 min, 10 cycles at 95 ˚C for 30s, at 63
˚C for 30s and 30 cycles at 95 ˚C for 10s, at 63 ˚C for 30s. Following SYBR Green-based
end-point RT-qPCR, the specificity of the amplification products was verified by
melting curve analysis. All reactions were run in duplicate and for all samples no-RT -
controls were run to exclude possible DNA contamination as well as NTC-controls to
exclude PCR contamination and primer-dimers. In addition to calibration curves,
positive control sample was included in each run.
     Reaction volume and amount of cDNA/DNA E reaction volume: 10µl, amount of cDNA: 2µl
     Primer, (probe), Mg++ and dNTP concentrations E Real_time qPCR: Probe conc. 200nM, primer conc.400nM, dNTP conc. Mg and
dNTP was included to Sensifast Lo-Rox Kit. Endpoint RT-PCR: Primer conc:
500nM, Dynamo HS Sybr Green 2X master mix(contains a hot-start version of a
modified
Tbr DNA polymerase, SYBR Green I,
optimized PCR buffer, 5 mM MgCl2, dNTP
     Polymerase identity and concentration E Real-time qPCR: Sensifast (Bioline), endpoint RT-qPCR: hot-start version of a
modified
Tbr DNA polymerase (Thermo Fisher Scientific)
     Buffer/kit identity and manufacturer E Real-Time qPCR: SensiFAST Probe Lo-ROX Kit (Bioline); Endpoint RT-qPCR:
Dynamo HS SYBR Green 2 x master Mix (Thermo Fisher Scientific)
     Exact chemical constitution of the buffer D
     Additives (SYBR Green I, DMSO, etc.) E Endpoint RT-qPCR: 5 x ROX (Thermo); (SYBR Green was included to kit in both
systems)
Manufacturer of plates/tubes and catalog number D
Complete thermocycling parameters E Real-time qPCR:thermocycling conditions 95 ˚C for 5 min, 40 cycles at 95 ˚C for 10s,
at 65 ˚C for 20s; Endpoint RT-qPCR thermocycling conditions 95 ˚C for 15 min, 10
cycles at 95 ˚C for 30s, at 63 ˚C for 30s and 30 cycles at 95 ˚C for 10s, at 63 ˚C for 30s
Reaction setup (manual/robotic) D
Manufacturer of qPCR instrument E Applied Biosystem 7500 Fast Real-Time PCR System (Life Tecnologies)
qPCR VALIDATION
Evidence of optimisation (from gradients) D
Specificity (gel, sequence,  melt, or digest) E Melting curve analysis, ramping from 63 ˚C to 95 ˚C.  All reactions were run in
duplicate and for all samples no-RT - controls were run to exclude possible
DNA contamination as well as NTC-controls to exclude PCR contamination
and primer-dimers.
For SYBR Green I, Cq of the NTC E Cq of the NTC was over 40 and in most cases not seen at all
Standard curves with slope and y-intercept E Endpoint RT-qPCR: Total CGB: y=-3.176 x 26.4, GAPDH y=3.381 x 25.7. Real-
time qPCR: hCGbeta type Iy=-3.423 x 31.2, hCGbeta type II y=-3.379 x 22.2,
GAPDH y=-3.482 x 21.8.
     PCR efficiency calculated from slope E Endpoint RT-qPCR: Total CGB: 106.8%, GAPDH 97.8%. Real-time qPCR:
hCGbeta type I 92,4%, hCGbeta type II 97,6%, GAPDH r2 =93,7%.
     Confidence interval for PCR efficiency or standard error D
     r2 of standard curve E Endpoint RT-qPCR: Total CGB: r2 =0.984 GAPDH r2 =0.992. Real-time qPCR:
hCGbeta type I r2 =0.944, hCGbeta type II r2 =0.986, GAPDH r2 =0.998.
Linear dynamic range E Standard curves for totalCGB  mRNA and GAPDH  for endpoint RT-qPCR were linear over
6 orders (CGB , r2 = 0.98) or 5 (GAPDH , r2 = 0.99) of magnitude. The standard curves for
real-time RT-qPCR for CGB type I and II were linear over 6 orders (CGB type I, r2 = 0.94
and CGB type II, r2 = 0.98) of magnitude and for GAPDH over 7 orders (r2 = 0.99) of
magnitude
     Cq variation at lower limit E 2 ˚C
     Confidence intervals throughout range D
Evidence for limit of detection E Lowest standard in standard curve
If multiplex, efficiency and LOD of each assay. E Lowest calibrator of each gene was used as a limit of detection in each run: for total
CGB  mRNA and GAPDH  mRNA in endpoint RT-qPCR,  0.01 ng of placental RNA, and
in real-time RT-qPCR for CGB  type I,  4 ng of T24 bladder carcinoma cell line RNA and
for CGB  type II and GAPDH , 0.005 ng of the JEG chorion carcinoma cell line RNA.
DATA ANALYSIS
qPCR analysis program (source, version) E 7500 Sofware v.2.0.6
     Cq method determination E The threshold is used to specify Cq values of samples
     Outlier identification and disposition E None of Cq was disposed
Results of NTCs E NTCs did not give any signal or there was very high Cq value (>40)
Justification of number and choice of reference genes E Based on earlier reports, GAPDH was chosen as a reference gene. The
suitability of it has been explained in the text.
Description of normalisation method E Normalisation were done by calculating the ratio of CGB/GAPDH mRNAs
Number and concordance of biological replicates D
Number and stage (RT or qPCR) of technical replicates E All RT-qPCR reactions were performed in duplicate
Repeatability (intra-assay variation) E
Reproducibility (inter-assay variation, %CV) D
Power analysis D
Statistical methods for result significance E Differences between various categories were analyzed using Mann-Whitney U-
test. Correlation between hCGβ mRNA and clinical variables was analyzed by
Spearman rank-order correlation test. Kaplan-Meier survival analysis and log-
rank test were used to estimate the effect of CGB gene expression on prostate
cancer-specific survival and overall survival.
Software (source, version) E IBM SPSS software (version 22.0)
Cq or raw data submission using RDML D
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the RNA was precipitated by adding a double volume of absolute ethanol and incubating at -70°C 
overnight. The precipitate was washed twice with 500 µl of 70% ethanol and centrifuged at 5200 g 
for 10 min at 4°C to re-pellet the sample. After the final wash, the pellet was dried at room 
temperature and dissolved in 20 µl of RNase-free water.  
The extracted total RNA was then DNase-treated by adding to 10 µg of RNA, 5 µl of 
10x DNase buffer (100 mM Tris, pH 7.5, 25 mM MgCl2, 5 mM CaCl2) and 10 units of DNase I  
and incubating for 30 min at 37 °C, after which the DNase was inactivated for 5 min at 70°C. RNA 
was then precipitated with 5 µl of 2 M sodium acetate (pH 4.0) and 140 µl of 100% ethanol 
overnight at -20 °C, after which the sample was centrifuged at 5200 g for 30 min at 4 °C. The 
supernatant was carefully removed and the RNA pellet washed with 200 µl of 70% ethanol, after 
which the sample was centrifuged at 5200 g for 20 min at 4 °C. The supernatant was removed, and 
the RNA was dissolved in 20 µl of RNase-free water. Total RNA from cell lines was isolated by 
Qiagen RNeasy as described by the manufacturer. 
Reverse Transcription and Exonuclease I treatment 
Total RNA (450 ng) was denaturated for 5 min at 70 °C and multiplex reverse-transcribed in 5 µl 
reaction volume with RevertAid Premium  reverse transcriptase (Thermo Fisher Scientific, 
Waltham, MA, USA) at 55°C for 30 min using gene-specific antisense primers  for CGB and 
GAPDH (Table 3a, 3b). After reverse transcription, the unbound reverse transcription primers were 
degraded by Exonuclease I (New England Biolabs, Ipswitch, MA, USA) at 42°C for 45 min.  
Primers and probes 
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Primers for endpoint RT-qPCR (total CGB and GAPDH) as well as primers and hydrolysis probes 
for TaqMan Chemistry RT-qPCR (CGB type I, CGB type II and GAPDH) were designed using 
OLIGO Primer Analysis Software, version 7.0 (Molecular Biology Insights, Colorado Springs, CO, 
USA) and their specificity was verified with BLAST. All known splicing variants of different genes 
were included. The primers were purchased from TAG Copenhagen (Copenhagen, Denmark). 
Sequences of primers and probes as well as all their target sequences and length of amplicons are 
shown in Tables 3a and 3b.  
 
PCR 
 
Real-time qPCR for GCB type I and type II as well as for GAPDH separately were carried out with 
SensiFAST Probe Lo-ROX Kit (Bioline) with 4 pmol of each primer and 2 pmol of hydrolysis 
probes in a final volume of 10 µl using Applied Biosystem 7500 Fast Real-Time PCR System (Life 
Technologies, Carlstad, CA) and thermocycling conditions 95 ˚C for 5 min, 40 cycles at 95 ˚C for 
10s, at 65 ˚C for 20s.  
Endpoint RT-qPCR for total CGB and GAPDH separately were carried out with 
Dynamo HS SYBR Green 2 x master Mix (Thermo Fisher Scientific) with 5 pmol of each primer in 
a final volume of 10.9 µl using Applied Biosystem 7500 Fast Real-Time PCR System (Life 
Tecnologies, Carlstad, CA) and thermocycling conditions 95 ˚C for 15 min, 10 cycles at 95 ˚C for 
30s, at 63 ˚C for 30s and 30 cycles at 95 ˚C for 10s, at 63 ˚C for 30s. Following SYBR Green-based 
end-point RT-qPCR, the specificity of the amplification products was verified by melting curve 
analysis. 
 All reactions were run in duplicate and for all samples no-RT - controls were run to 
exclude possible DNA contamination as well as NTC-controls to exclude PCR contamination and 
primer-dimers. Positive control sample was included in each run. 
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Quantification of RT-PCR results 
 
Three different dilution of RNA isolated from cell lines or placental tissue were used as calibrators 
in every PCR run to confirm inter-assay reproducibility as follows: For total CGB mRNA and 
GAPDH mRNA in endpoint RT-qPCR, we used 100 ng, 1 ng, and 0.01 ng of placental RNA. In 
real-time RT-qPCR for CGB type I, 400 ng, 40 ng, and 4 ng of T24 bladder carcinoma cell line 
RNA and for CGB type II and GAPDH, 50 ng, 0.05 ng, and 0.005 ng of the JEG chorion carcinoma 
cell line RNA was used. Lowest calibrator of each gene was used as the limit of detection in each 
run. The relative expression of total CGB as well as CGB type I and II mRNAs were calculated by 
normalizing mRNA against GAPDH mRNA in each sample.  
 Suitability of GAPDH as a reference gene was tested between benign (n = 111) and 
malignant (n = 333) sample cohort. In this experiment 1000 molecules of genomic DNA was used 
as an internal control in DNase-treated RNA-samples and the ratio of mRNA to genomic DNA was 
measured. No difference of GAPDH mRNA expression levels between malignant and benign 
samples were seen (data not shown). 
 
Statistical Analyses 
 
Statistical analyses were performed using IBM SPSS software (version 22.0). Differences between 
various categories were analyzed using Mann-Whitney U-test. Correlation between CGB mRNAs 
and clinical variables was analyzed by Spearman rank-order correlation test. Kaplan-Meier survival 
analysis and log-rank test were used to estimate the effect of CGB gene expression on prostate 
cancer-specific survival and overall survival. Survival time was calculated from the date of radical 
prostatectomy to the date of last follow-up or death. In analysis of cancer-specific survival, death 
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from prostate cancer was considered as the event. In analysis of overall survival, the event was all 
causes of death. All tests were two-sided and P-values of less than 0.05 were considered significant.  
 
Results 
Sensitivity and specificity of the assays 
Dynamic range of each gene was measured by standard curves. Standard curves for total CGB 
mRNA and GAPDH for endpoint RT-qPCR were linear over 6 (CGB, r2 = 0.98) or 5 orders 
(GAPDH, r2 = 0.99) of magnitude (Suppl. Figure S1.).  
Figure 1. CGB mRNA levels in non-cancerous and cancerous prostate tissue. The significance of 
the difference was calculated by the Mann–Whitney U-test. Type I (A), type II (B) and total CGB 
mRNA (C) expression levels in non-cancerous and cancerous prostatic tissue showing significantly 
higher expression in non-cancerous tissue. 
10 
 
 
11 
 
Figure 2. Kaplan–Meier analysis of cancer specific survival of prostate cancer patients. (A) Tissue 
mRNA concentration of CGB type II in the lower quartile predicts shorter disease specific survival 
of prostate cancer patients (p = .001). (B) Grade group 3–5 predicts shorter disease specific survival 
of prostate cancer patients (p < .0001). (C) Tumor stage 3–4 predicts shorter disease specific 
survival of prostate cancer patients (p < .0001). 
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The standard curves for real-time RT-qPCR for CGB type I and II were linear over 6 orders (CGB 
type I, r2 = 0.94 and CGB type II, r2 = 0.98) of magnitude and for GAPDH over 7 orders (r2 = 0.99) 
of magnitude (Suppl. Figure S2.). Primers for type I and II are common to all genes (CGB1, 2, 3, 5, 
7 and 8). Probe to type I CGB detects only CGB7 and probe to type II CGB detects CGB1, 2, 3, 5 
and 8 (Table 3b). The specificity of CGB type I and II hydrolysis probes were studied using 
dilutions of T24 and JEG-3 cell lines, respectively. As shown before, type I mRNA was expressed 
in the T24 cell line and type II mRNA in JEG-3 cells [16]. The efficiency of different RT-qPCR 
methods were between 92-106 % (Suppl. Table S1). 
 
Expression of type I and II CGB transcripts in non-cancerous and cancerous prostate tissue 
 
CGB type I and II mRNA was determined in 114 malignant and 54 non-cancerous samples. RT-
qPCR results for CGB type I mRNA (gene 7) were detected for 84% (96/114) of the tumor samples 
and for 91% (49/54) of the samples from adjacent non-cancerous tissue. CGB type II mRNA (genes 
1, 2, 3, 5, 8) was detected in 96% (109/114) of the tumor samples and in 98% (53/54) of adjacent 
non-cancerous tissue. The difference between cancerous tissue and non-cancerous tissue was 
statistically significant for both type I CGB and type II CGB mRNA (Mann-Whitney U-test; p < 
0.0001 and p = 0.007, respectively) (Figure 1a and b), showing strong downregulation of both 
mRNA types in cancer tissue.  
 
Expression of total CGB mRNA in non-cancerous and cancerous prostate tissue 
 
Total CGB mRNA expression was determined in 178 of 193 malignant prostatic tissues, in 62 of 74 
non-cancerous prostatic tissues, and in all 47 BPH samples by RT-qPCR system, which detects all 
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ten hCGβ protein-coding transcripts from genes CGB 1, 2, 3, 5, 7, and 8. Total CGB expression was 
detected in 79% (141/178) of the tumor samples and in all non-cancerous (62/62) and BPH (47/47) 
samples.  The median level of total CGB mRNA differed significantly between cancerous and non-
cancerous tissue, showing strong downregulation in cancer (Mann-Whitney U-test; p < 0.0001) 
(Figure 1c).  
 
Correlation between clinical characteristics and survival 
There was a highly significant inverse correlation between total CGB mRNA and tumor stage 
(Spearman’s rho correlation test; p = 0.002, correlation coefficient -0.240) and serum PSA (p = 
0.019, correlation coefficient -0.187). The total CGB mRNA correlated positively with both type I 
(p < 0.0001, correlation coefficient 0.402) and type II mRNAs (p < 0.0001, correlation coefficient 
0.299). No correlation between total CGB and Gleason score was found (p = 0.102, correlation 
coefficient -0.124). 
Type I mRNA correlated negatively with tumor stage (p = 0.003, correlation 
coefficient -0.280), but showed no correlation with serum PSA or Gleason score. Type II mRNA 
correlated negatively with Gleason score (p = 0.003, correlation coefficient -0.271) and tumor stage 
(p = 0.014, correlation coefficient -0.232), but showed no correlation with serum PSA. 
In Kaplan-Meier analysis, patients with low CGB type II mRNA (below the 25 
percentile), Grade group 3 - 5, or pT 3-4 all correlated with shorter cancer-specific survival (Figure 
2a, b, and c), but none of them with overall survival.  In Kaplan-Meier analysis, the type I mRNA or 
total CGB mRNA expression did not correlate with cancer-specific survival or overall survival.  
 
Discussion 
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We found that both type I and type II CGB genes are expressed in non-cancerous and cancerous 
prostate tissue and report for the first time that they both are significantly lower in cancerous than 
non-cancerous prostatic tissue. Furthermore, in Kaplan-Meier analysis, low type II CGB mRNA is 
associated with short cancer-specific survival. As expected, Gleason score and stage were also 
strongly associated with cancer-specific mortality. Dirnhofer et al. [11] found expression of CGB 
genes in both cancerous and BPH tissue and further detected hCG protein in culture fluid of BPH 
tissue explants. Span et al. [10] noted lower expression of total CGB mRNA in cancerous than non-
cancerous prostatic tissue, but they detected no significant difference between these tissues in 
expression level of type II genes. They did not study the expression level of type I genes. We show 
here for the first time that type I genes are also downregulated in cancer. This might explain the 
lower expression of total CGB mRNA in cancer found by Span et al. [10]. Despite the stronger 
downregulation of type I, only low expression of type II mRNA was a significant prognostic factor 
in the present study.  
        In publicly available databases there are only few studies with CGB mRNA 
expression data. In cBioPortal [17] CGB mRNA can be found in six different cohorts, one with 
survival data.  In that study, mRNA upregulation of all CGB genes was found in approximately 5% 
of the patients (n= 498). In Kaplan-Meier analysis no difference was found between cases with 
mRNA upregulation and cases without mRNA upregulation of any CGB gene.  In ProgGeneV2 [18] 
two additional cohorts have information about CGB mRNA. No differences between high and low 
expression of CGB gene types I or type II was seen in Kaplan-Meier analysis. When individual 
CGB genes were analyzed, patients with high CGB1 mRNA expression had statistically shorter 
relapse free survival. However, the sample size in the cohorts was small (n = 110, and n = 91) and 
follow-up time was shorter (5 to 8 years) than in the present study. 
Earlier, Bostwick et al. [19] showed that hCG protein expression can be detected in 
prostate and prostate cancer tissue by immunohistochemistry (IHC).  The expression localized to 
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neuroendocrine cells and was more common in non-cancerous prostatic tissue (100%) than in 
intraepithelial neoplasia (30%) or adenocarcinoma (22%) [19].  Their results are in agreement with 
the mRNA results of Span et al. [10] and our findings.  The adverse prognosis associated with 
reduced CGB mRNA expression in prostate cancer is surprising as elevated serum concentrations of 
hCGβ protein have been found to indicate adverse prognosis in many other cancers [9, 20-23]. 
Interestingly, we have previously observed a discrepancy between hCGβ concentrations in serum 
and tissue expression of CGB mRNA also in kidney and bladder cancer [24-25]. Moreover, 
increased expression of type II CGB genes has been shown to correlate with early relapse in breast 
cancer [26]. The cause of the discrepancy in expression of CGB mRNA between prostate and breast 
cancer tissue is unclear. One potential explanation is different expression or function of 
transcription factor Ets-2, which is involved in protein kinase A-stimulated CGB5 expression [27]. 
Ets-2 is upregulated in tumor stromal fibroblasts and has been shown to promote angiogenesis in 
breast cancer [28]. However, in the prostate cancer VCaP cell line, overexpression of wild-type Ets-
2 results in decreased migration, invasion, and proliferation. A mutation (R437C) in the Ets-2 gene 
has opposite effects in these cells, indicating that Ets-2 has different roles in prostate and breast 
cancer [29]. 
In our earlier study on bladder cancer, we found that the ratio of type II to type I 
(primers detecting CGB2 and CGB7) mRNA increased with increasing stage and grade of the 
tumor. In the present study, we found a significant decrease of type I mRNA (primers detecting 
only CGB7), and the ratio of type II to type I mRNA was significantly higher (p < 0.0001) in 
cancerous tissues than in non-cancerous tissues, consistent with our earlier results for bladder 
cancer [8]. No correlation, however, was found between type II to type I CGB mRNA ratio and 
survival time of the patients in the present prostate cancer material.  
Our present RT-PCR assay measures both CGB1 and 2 together with the classical type 
II genes, CGB3, CGB5 and 8 whereas the method of Span et al measured only CGB3, 5 and 8. 
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Thus, the difference between the results in our studies and that those of Span et al [10] may due to 
decreased expression of CGB1 and/or CGB2 in prostate cancer tissue. However, separate RT-PCR 
methods for CGB1 and 2 are needed to show their real expression levels and correlation with 
aggressive disease.  
A strength of this study is the very long follow-up (median 16 years, maximum 26 
years), allowing long-term prognosis to be reliably evaluated. However, we studied patients treated 
by radical prostatectomy, and thus, whether CGB gene expression correlates with relapse and 
survival also in patients under active surveillance remains unknown. Our patients cohort consisted 
of hormone-naïve (no neoadjuvant treatment) surgically treated patients. Thus, the biological 
differences between samples are not affected by any preoperative treatments, and the disease specific 
variation between patients is well detectable. However, as the study is retrospective, we cannot fully 
control the effects of any possible secondary treatments to the patients’ survival. An important future 
goal is to determine whether survival can be predicted on the basis of CGB gene expression also in 
these patients.  
We conclude that reduced CGB type II mRNA expression in prostate cancer tissue is 
associated with adverse outcome of prostate cancer patients treated by radical prostatectomy.  
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Table 1. Clinical characteristics of PCa patients (n = 193) 
  
Age at surgery, years; median (range) 64 (45 - 76) 
Years of collection 1984 - 1998 
Dead from PCa 18 
Dead from other cause 72 
Tumor Gleason score  
≤ 6 56 
7 118 
8 - 9 17 
NA 2 
ISUP Grade group  
1 56 
2 52 
3 66 
4 14 
5 3 
NA 2 
Pathological tumor stage   
2 110 
3 72 
4 1 
NA 10 
Patient follow-up, years; median (range) 16.10 (0.57 - 26.10) 
Serum PSA, µg/l    
<4 13 
4 - 10 66 
> 10  95 
NA 26 
Patients receiving secondary therapy 53 
Patients receiving tertiary therapy 24 
 
Table 2. Number of samples analyzed with different RT-qPCRS.  
        
Total no. of samples Malignant 193  Benign 74 
 
samples 
analysed 
samples with 
detectable CGB 
mRNA (%) 
samples 
analysed 
samples with 
detectable CGB mRNA 
(%) 
Total CGB mRNA  178/193 141/178 (79%) 62/74 62/62 (100%) 
Type I CGB mRNA  114/193 96/114 (84%) 54/74 49/54 (91%) 
Type II CGB mRNA  114/193 109/114 (96%) 54/74 53/54 (98%) 
 
Table 3a. Primers used with SYBR Green Q-RT-PCR chemistry (endpoint RT-qPCR). 
   
Primer Sequence Gene Accession Number 
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GAPDH (127 bp)   
forward GGAAATTCCATGGCACCGTCA ENSG00000111640 
reverse CGACGTACTCAGCGCCAGCAT
C 
 
   
CGB total (130 bp)   
forward CTGCCCCGTGTGCATCACC ENSG00000267631 (CGB1) 
reverse CTCGAAGCGCACATCGCGGTA ENSG00000104818 (CGB2) 
  ENSG00000104827 (CGB) 
  ENSG00000189052 (CGB5) 
  ENSG00000196337 (CGb7) 
  ENSG00000213030 (CGB8) 
 
Table 3b. Nucleotide sequences of primers and probes used with TaqMan probe RT-qPCR chemistry. 
   
Primer/Probe Sequence Gene Accession Number 
   
GAPDH (97 bp)   
forward primer GCCCCAGCAAGAGCACAA ENSG00000111640 
reverse primer TGTGAGGAGGGGAGATTCAGT  
probe FAM-ACTCCCCAGCAGTGAGGGTCT-MGB 
   
CGB type I and II (98 bp)  
forward primer CTGCTGTTGCTGCTGCT ENSG00000267631 
(CGB1) 
reverse primer TTCTCCACAGCCAGGGT ENSG00000104818 
(CGB2) 
  ENSG00000104827 (CGB) 
  ENSG00000189052 
(CGB5) 
  ENSG00000196337 
(CGB7) 
  ENSG00000213030 
(CGB8) 
   
CGB type I/probe FAM- ACATGGGCATCCAGGGAGATGC –MGB ENSG00000196337 
(CGb7) 
   
CGB type II/probe VIC-ACATGGGCATCCAAGGAGCCG-MGB ENSG00000267631 
(CGB1) 
  ENSG00000104818 
(CGB2 
  ENSG00000104827 (CGB) 
  ENSG00000189052 
(CGB5) 
  ENSG00000213030 
(CGB8) 
 
Figure legends 
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Figure 1. CGB mRNA levels in non-cancerous  and cancerous prostate tissue. The significance of 
the difference was calculated by the Mann-Whitney U-test. Type I (A), type II (B) and total CGB 
mRNA (C) expression levels in non-cancerous and cancerous prostatic tissue showing significantly 
higher expression in non-cancerous tissue. 
Figure 2. Kaplan-Meier analysis of cancer specific survival of prostate cancer patients. A.  Tissue 
mRNA concentration of CGB type II in the lower quartile predicts shorter disease specific survival 
of prostate cancer patients (p = 0.001). B. Grade group 3-5 predicts shorter disease specific survival 
of prostate cancer patients (p < 0.0001). C. Tumor stage 3-4 predicts shorter disease specific 
survival of prostate cancer patients (p < 0.0001). 
Supplemental Figure S1. Standard curves for total CGB (A) and GAPDH (B) endpoint RT-qPCR 
using dilutions of placental RNA.  
Supplemental Figure S2. Standard curves for CGB type I RT-qPCR using dilutions of cell line JEG-
3 RNA (A), CGB type II using dilutions of cell line T4 RNA (B) and GAPDH using dilutions of 
cell line JEG-3 RNA(C).  
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